R&D Views & Analysis | pharmaphorum

Views & Analysis

engineering and genetic editing through the Crispr technique. DNA chain breaking down. 3D rendering

AstraZeneca looks to CRISPR to boost success rates

Between 2005 and 2010 AstraZeneca‘s success rates for taking drugs from candidate nomination to phase III completion were at 4%, below an already-low industry standard of 5%.

Views & Analysis

Dutch biotech Pharming plans to challenge big pharma in rare...

The introduction of Shire’s preventive treatment for hereditary angioedema has shaken up the market for drugs for this rare disease.

Views & Analysis

Four steps for more patient centric trials

Medidata’s general manager & senior vice president EMEA, Christian Hebenstreit, on placing the patient experience at the heart of clinical trials

Views & Analysis

Is the pharma gender gap starting to close?

When Emma Walmsley took the reins of GlaxoSmithKline (GSK) in 2016, becoming the first woman to head up a major pharmaceutical company, it was headline news.

Views & Analysis

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Merck & Co is enjoying blockbuster revenues as its cancer immunotherapy Keytruda is becoming standard of care in a range of cancers.

Views & Analysis

Commercialising orphan drugs: the pharmaphorum podcast

In episode 4 of the podcast pharmaphorum talked to Dr Joe Wiley, CEO of UK-based biopharmaceutical company Amryt Pharma, about its strategy and work in the rare diseases and gene therapy space.

AstraZeneca looks to CRISPR to boost success rates

Dutch biotech Pharming plans to challenge big pharma in rare...

Four steps for more patient centric trials

Is the pharma gender gap starting to close?

Merck & Co’s cancer blockbuster Keytruda funds cutting edge ...

Commercialising orphan drugs: the pharmaphorum podcast

Ipsen' Bylvay fluffs its lines in biliary atresia trial

Discover a new era of healthcare panel engagement: Grounded ...

Views & Analysis

Editor's Picks